心力衰竭采用螺内酯联合厄贝沙坦治疗的效果分析  

Analysis of the Effect of Spironolactone Combined with Irbesartan in the Treatment of Heart Failure

作　　者：练育芳[1] 卢少堂 LIAN Yu-fang;LU Shao-tang(Department of Cardiology,Dongtai People's Hospital,Dongtai,Jiangsu Province,224200 China)

机构地区：[1]江苏省东台市人民医院心血管内科,江苏东台224200

出　　处：《系统医学》2020年第24期61-63,共3页Systems Medicine

摘　　要：目的探析心力衰竭患者采用螺内酯联合厄贝沙坦治疗的临床疗效。方法该文将该院2019年1-12月接受的82例心力衰竭患者随机分为两组,接受厄贝沙坦治疗的41例患者为对照组,接受螺内酯联合厄贝沙坦治疗的41例患者为观察组,对比患者血压水平、治疗后疗效、心功能及不良反应差异。结果观察组LVEF(42.67±4.10)%、HR(75.24±3.73)次/min、CO(4.38±1.07)L/min、SV(63.59±3.18)mL,同对照组对比,差异有统计学意义(t=11.204、22.240、2.609、23.652,P<0.05)。观察组治疗后,患者收缩压(115.76±8.59)mmHg、舒张压(72.49±4.66)mmHg,相比于治疗前差异有统计学意义(t=7.102、4.781,P<0.05);患者经临床治疗,观察组总有效率38(92.68%),优于对照组30(73.17%),差异有统计学意义(χ^2=5.513,P<0.05);观察组发生窦性心动过缓等不良反应3例,发生率7.32%,低于对照组的12例(29.27%),差异有统计学意义(χ^2=6.609,P<0.05)。结论心力衰竭患者采用螺内酯联合厄贝沙坦治疗,相比于厄贝沙坦单独治疗,更具有安全性,患者心功能得以有效改善,稳定控制了患者的病情。Objective To explore the clinical efficacy of spironolactone combined with irbesartan in patients with heart failure.Methods In this paper,82 patients with heart failure received in the hospital from January 2019 to December 2019 were randomly divided into two groups.41 patients who received irbesartan were treated as the control group,and those who received spironolactone combined with irbesartan were treated as the control group.41 patients were in the observation group,and the differences in blood pressure level,curative effect after treatment,cardiac function and adverse reactions were compared.Results LVEF(42.67±4.10)%,HR(75.24±3.73)times/min,CO(4.38±1.07)L/min,SV(63.59±3.18)mL in the observation group were compared with the control group,the difference was statistically significant(t=11.204,22.240,2.609,23.652,P<0.05).After treatment in the observation group,the patient's systolic blood pressure(115.76±8.59)mmHg and diastolic blood pressure(72.49±4.66)mmHg were significantly different from those before treatment,the difference was statistically significant(t=7.102,4.781,P<0.05);after clinical treatment,the patients in the observation group of the total effective rate was 38(92.68%),which was better than the control group 30(73.17%),the difference was statistically significant(χ^2=5.513,P<0.05);the observation group had 3 cases of adverse reactions such as sinus bradycardia,the incidence rate was 7.32%,which was lower than the control group 12(29.27%),the difference was statistically significant(χ^2=6.609,P<0.05).Conclusion The treatment of heart failure patients with spironolactone combined with irbesartan is safer than irbesartan alone.The patient's heart function can be effectively improved and the patient's condition can be stably controlled.

关 键 词：心力衰竭 螺内酯 厄贝沙坦 治疗效果 

分 类 号：R4[医药卫生—临床医学]